Open Access
Tableau I.
Principaux essais cliniques utilisant une combinaison d’anticorps en thérapie anti-infectieuse. gp120: glycoprotéine d’enveloppe (Env) ; V3 glycan site Env: site de glycosylation de la région V3 de gp120.
| Pathogène | Anticorps | Formulation | Cibles | Phase clinique | Date |
|---|---|---|---|---|---|
| Virus de l’immunodéficience humaine | 3BNC117 + 10-1074 | Séparée | CD4bs-gp120 + V3 glycan site Env | Phase I | 2018 |
| VRC01LS + 10-1074 | Séparée | CD4bs-gp120 + V3 glycan site Env | Phase I/II | 2018 | |
| 10E8VLS + VRC07-523LS | Séparée | gp41 + CD4bs-gp120 | Phase I | 2018 | |
| VRC01LS + VRC07-523LS | Séparée | CD4bs-gp120 + CD4bs-gp120 | Phase I | 2018 | |
| PGDM1400 + PGT121 | Séparée | V2-loop Env + V3 glycan site Env | Phase I | 2017 | |
| 2G12 + 4E10 + 2F5 | Unique | Env | Phase I/II | 2007 | |
| Virus de la grippe | CT-P27 | Unique | Hémaglutinines groupe 1 et 2 | Phase IIb | 2018 |
| CR8020 + CR6261 | Séparée | Hémaglutinines | Phase IIa | 2014 | |
| Clostridium difficile | MK-6072 + MK-3415A | Séparée | Toxines A et B | Phase III | 2018 |
| MK-3415 + MK-6072 + MK-3415A | Séparée | Toxines A et B | Phase III | 2018 | |
| MK-6072 + MK-3415A | Séparée | Toxines A et B | Phase III | 2018 | |
| GS-CDA1 + MDX-1388 | Séparée | Toxines A et B | Phase II | 2010 | |
| Shigella | caStx1 + CaStx2 | Unique | Toxines Shiga 1 et 2 | Phase II | 2013 |
| Virus de la rage | SYN023 (CTB011 + CTB012) | Unique | Rabies G protein | Phase I | 2018 |
| CL184 | Unique | Rabies G protein | Phase II | 2013 | |
| Virus respiratoire syncitial | Motavizumab (MEDI-524) + Palivizumab | Séparée | RSV | Phase II | 2012 |
| Clostridium botulinum | NTM-1633 (XE02 + XE06 + XE17) | Unique | Neurotoxines E1, E3 et E4 | Phase I | 2018 |
| NTM-1634 (XC41+XC42+XC44+XC84) | Unique | Neurotoxines C et D | Phase I | 2018 | |
| NTM-1632 (3 Abs) | Unique | Neurotoxine B | Phase I | 2017 | |
| Xoma 3AB | Unique | Neurotoxine A | Phase I | 2014 | |
| Virus Ebola | GamEMab | Unique | Ebola | Phase I | 2018 |
| Zmapp (Zmab + c2G4 + c4G7) | Unique | Protéine GP | Phase I | 2018 | |
| REGN3470+3471+3479 | Unique | protéine GP | Phase I | 2018 | |
| MERS coronavirus | REGN3048 + REGN3051 | Séparée | Protéine Spike | Phase I | 2018 |
| Staphylococcus aureus | ASN100 (ASN-1 + ASN-2) | Unique | a-hémolysine et leukotoxines | Phase II | 2018 |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.